Jacob Korach, MD
Long-term maintenance therapy with olaparib (Lynparza) tablets demonstrated a low rate of treatment discontinuation and tolerable safety profile in patients with platinum-sensitive recurrent ovarian cancer, according to an analysis from the phase III SOLO-2 trial.1
After ≥2 years of olaparib, the most common AEs were anemia (19.4%), nausea (17.7%), and vomiting (14.5%). The most common AEs with onset after ≥2 years were diarrhea (8.5%), abdominal pain (5.1%), and upper abdominal pain (5.1%).
- Korach J, Freyer G, Banerjee S, et al. Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial. In: Proceedings from the 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. Abstract 952P. academic.oup.com/annonc/article/29/suppl_8/mdy285.160/5141893.
- Pujade-Lauraine E, Ledermann JA, Selle F, et al; SOLO2/ENGOT-Ov21 Investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;18(9)1274-1284. doi: 10.1016/S1470-2045(17)30469-2.
- Gourley C, Friedlander M, Matalonis U, et al. Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol. 2017;35(suppl; abstr 5533). doi: 10.1200/JCO.2017.35.15_suppl.5533.
... to read the full story